Flow cytometric analysis of CD13 expression on human peripheral blood. Human whole blood was stained with either Purified Mouse IgG1, κ Isotype Control (Cat. No. 555746; dashed line histogram) or Purified Mouse Anti-Human CD13 (Cat. No. 555393; solid line histogram), followed by FITC Goat Anti-Mouse IgG/IgM (Cat. No. 555988). Erythrocytes were lysed with BD FACS™ Lysing Solution (Cat. No. 349202). Fluorescence histograms depicting CD13 (or Ig isotype control) expression were derived from gated events with the side and forward light-scattering characteristics of monocytes (left figure) or granulocytes (right figure). Flow cytometry was performed on a BD FACScan™ system.
Flow cytometric analysis of CD13 expression on human peripheral blood. Human whole blood was stained with either Purified Mouse IgG1, κ Isotype Control (Cat. No. 555746; dashed line histogram) or Purified Mouse Anti-Human CD13 (Cat. No. 555393; solid line histogram), followed by FITC Goat Anti-Mouse IgG/IgM (Cat. No. 555988). Erythrocytes were lysed with BD FACS™ Lysing Solution (Cat. No. 349202). Fluorescence histograms depicting CD13 (or Ig isotype control) expression were derived from gated events with the side and forward light-scattering characteristics of monocytes (left figure) or granulocytes (right figure). Flow cytometry was performed on a BD FACScan™ system.
Product Details
BD Pharmingen™
ANPEP; APN; Aminopeptidase N; Alanyl aminopeptidase; LAP1; PEPN
Human (QC Testing)
Mouse IgG1, κ
Human AML Cells
Flow cytometry (Routinely Tested), Immunohistochemistry-frozen (Tested During Development)
0.5 mg/ml
IV M44, M209
AB_395794
Aqueous buffered solution containing ≤0.09% sodium azide.
RUO
Preparation And Storage
Store undiluted at 4°C. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
Product Notices
- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- An isotype control should be used at the same concentration as the antibody of interest.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- Sodium azide is a reversible inhibitor of oxidative metabolism; therefore, antibody preparations containing this preservative agent must not be used in cell cultures nor injected into animals. Sodium azide may be removed by washing stained cells or plate-bound antibody or dialyzing soluble antibody in sodium azide-free buffer. Since endotoxin may also affect the results of functional studies, we recommend the NA/LE (No Azide/Low Endotoxin) antibody format, if available, for in vitro and in vivo use.
- Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
Companion Products
Purified Mouse IgG1, κ Isotype Control RUO
Size
0.1 mg
Cat No.
555746
FITC Goat Anti-Mouse IgG/IgM RUO
Size
0.5 mg
Cat No.
555988
.png?imwidth=320)
555393 Rev. 9
Antibody Details
WM15
The WM15 monoclonal antibody specifically binds to CD13, the 150 kDa Type II integral membrane glycoprotein which is also known as aminopeptidase N. The CD13 antigen is the receptor for human coronavirus 229E, the causative agent for some cases of upper respiratory infection. This antibody binds to GM-progenitor cells, granulocytic and monocytic cells, and mast cells, but not to lymphocytes, platelets or erythrocytes. Aminopeptidase N is involved in the metabolism of many regulatory peptides.
555393 Rev. 9
Format Details
Purified
Tissue culture supernatant is purified by either protein A/G or affinity purification methods. Both methods yield antibody in solution that is free of most other soluble proteins, lipids, etc. This format provides pure antibody that is suitable for a number of downstream applications including: secondary labeling for flow cytometry or microscopy, ELISA, Western blot, etc.
Purified
555393 Rev.9
Citations & References
View product citations for antibody "555393" on CiteAb
Development References (6)
-
Barclay NA, Brown MH, Birkeland ML, et al, ed. The Leukocyte Antigen FactsBook. San Diego, CA: Academic Press; 1997.
-
Favaloro EJ, Bradstock KF, Kabral A, Grimsley P, Zowtyj H, Zola H. Further characterization of human myeloid antigens (gp160,95; gp150; gp67): investigation of epitopic heterogeneity and non-haemopoietic distribution using panels of monoclonal antibodies belonging to CD-11b, CD-13 and CD-33. Br J Haematol. 1988; 69(2):163-171. (Biology). View Reference
-
Favaloro EJ, Moraitis N, Bradstock K, Koutts J. Co-expression of haemopoietic antigens on vascular endothelial cells: a detailed phenotypic analysis. Br J Haematol. 1990; 74(4):385-394. (Biology). View Reference
-
Favaloro EJ, Moraitis N, Koutts J, Exner T, Bradstock KF. Endothelial cells and normal circulating haemopoietic cells share a number of surface antigens. Thromb Haemost. 1989; 61(2):217-224. (Biology). View Reference
-
Knapp W. W. Knapp .. et al., ed. Leucocyte typing IV : white cell differentiation antigens. Oxford New York: Oxford University Press; 1989:1-1182.
-
Yang P, Wang X. COVID-19: a new challenge for human beings.. Cell Mol Immunol. 2020; 17(5):555-557. (Biology). View Reference
555393 Rev. 9
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.